While recent FDA approvals for ADCs like Enhertu have reshaped oncology, the industry is hitting a critical plateau: resistance and recurrence. Emerging clinical evidence reveals that single-payload ADCs often struggle to eliminate diverse tumor clones. When a portion of the tumor escapes, the hope for a durable response vanishes. This clinical "escape act" is primarily driven by two formidable hurdles: acquired payload resistance and antigen heterogeneity.

At Biocytogen, we are tackling these challenges head-on with next-generation strategies designed to overcome tumor complexity and redefine the future of ADC therapy.

Challenge 1: Acquired Payload Resistance 

Conventional single-payload ADCs are inherently vulnerable to resistance. Because their antitumor activity relies on a single cytotoxic mechanism, tumor cells that adapt can rapidly render the payload ineffective. 

► Biocytogen’s Solution: Dual-Payload Strategy

Payload Characteristics and Their Synergistic Benefits When Combined.

► Proof-of-Concept Validation with Dual-Payload Strategy:

Dual-payload Trastuzumab (anti-HER2) ADC demonstrates preserved HER2 binding, excellent stability and superior antitumor efficacy in vivo.

(A) Trastuzumab is conjugated with two cytotoxic payloads: vcMMAE (DAR=2) and BLD1102 (linker+BCPT02, DAR=4). (B) The dual-payload ADC retains HER2 binding comparable to unconjugated trastuzumab and single-payload ADC in cells. (C) Favorable pharmacokinetics with sustained ADC exposure. (D) In a HER2 esophageal PDX model, the dual-payload ADC achieves superior tumor growth inhibition (red line) compared with single-payload ADCs or their combination.

Challenge 2: Antigen Heterogeneity

Even when payload resistance is addressed, tumor antigen diversity remains a major obstacle. Single-target therapies often leave behind tumor cells with variable antigen expression, allowing the cancer to survive and recur.

► Biocytogen’s Solution: Dual Targeting to Overcome Antigen Escape

To address tumor heterogeneity at the antigen level, Biocytogen employs a dual-targeting approach that simultaneously engages Integrin β6 (ITGB6) and B7-H3. 

Why ITGB6 and B7-H3 are high-value therapeutic targets:

ITGB6

• Tumor-selective overexpression in multiple aggressive solid tumors
• Drives invasion and TGF-β–mediated immune exclusion, linking it to poor prognosis
• Cell-surface accessibility with strong antibody binding potential
• Efficient internalization, making it highly suitable for ADC payload delivery

B7-H3

• Broad solid tumor expression with limited normal tissue distribution
• Immune checkpoint function, contributing to T-cell suppression
• High surface density, enhancing antibody engagement
• Demonstrated ADC tractability, with multiple clinical-stage programs validating internalization and payload delivery

Combining both targets makes strategic sense for several reasons:

• Complementary Mechanisms: ITGB6 promotes invasion and immune exclusion, while B7-H3 mediates immune suppression— attacking two distinct but cooperative tumor survival pathways.
• Enhanced Tumor Coverage: Targeting two antigens broadens tumor cell coverage and mitigates heterogeneity-driven relapse.
• Improved Payload Delivery: Two internalizing targets increase ADC uptake and cytotoxic efficiency.
• Better Therapeutic Window: Both targets exhibit limited normal tissue expression, offering excellent therapeutic window.
• Competitive Differentiation: While B7-H3 is an established and competitive ADC target, integrating ITGB6 introduces mechanistic depth and strategic differentiation.

By incorporating ITGB6 alongside B7-H3, Biocytogen enhances biological breadth while securing a clear positioning advantage in an increasingly crowded ADC landscape.

► The B7-H3 and ITGB6 ADC Landscape:

BCG048: Our First-in-Class Dual-Payload, Dual-Target ADC Asset

► Key Features:

1. Fully Human Common Light Chain Backbone: RenLite^® antibodies use a common light chain to eliminate mispairing, ensuring seamless assembly and simplified manufacturing of fully human bispecifics.
2. Novel Dual-Target Strategy: Simultaneously targets ITGB6 and B7-H3—two clinically relevant, overexpressed solid tumor antigens—to improve tumor specificity and address heterogeneity.
3. Dual-Payload Platform: Combines vcMMAE (validated microtubule inhibitor, DAR=2) with proprietary BCPT02 (DAR=4), a highly potent TOP1 inhibitor with greater cytotoxic activity than DXd, enabling complementary mechanisms of action.
4. Robust Antitumor Performance:
   • The ITGB6×B7-H3 bsAb (unconjugated) shows enhanced internalization in dual-positive tumor cells (Figure 1).
   • The ITGB6×B7-H3 bsAb (vcMMAE-conjugated) demonstrated improved efficacy in CDX models as proof of concept for dual targeting.
   • BCG048 (dual-payload) shows synergistic effects over single-payload ADCs and outperforms benchmark ADC comparators in vivo (Figure 2).
5. Intellectual Property: A PCT patent application has been filed.
6. Broad Indications: Esophageal carcinoma, head and neck squamous cell carcinoma, bladder carcinoma, pancreatic adenocarcinoma, and NSCLC.

► Data Highlight:

Figure 1: BCG048 (bsAb-5) showed synergistic effects and enhanced internalization across all tumor cell lines, independent of ITGB6 and B7-H3 expression levels. 

Figure 2: BCG048 showed superior antitumor efficacy with dual-payload (red line) versus single-payload ADCs (top) and outperformed benchmark ADCs (bottom) in the colorectal PDX model.

Partnering Opportunities:

BCG048 represents a differentiated, first-in-class dual-target, dual-payload ADC with compelling preclinical validation and strong IP protection. We welcome strategic partnerships to accelerate clinical development and unlock its full potential for patients with high unmet need in solid tumors. 👉 Contact us today!

Frequently Asked Questions (FAQs):

1. What makes the BCG048 bsAD2C different from standard single-payload ADCs? 

BCG048 is designed as a first-in-class dual-payload bispecific antibody-drug conjugate (bsAD2C) asset. While clinical evidence shows that single-payload ADCs often fail to eliminate all tumor clones, BCG048 addresses tumor heterogeneity by simultaneously targeting two overexpressed solid tumor antigens: ITGB6 and B7-H3. Furthermore, it delivers two complementary cytotoxic payloads to provide a multi-dimensional attack, allowing it to outperform benchmark ADC comparators in vivo.

2. How does a dual-payload ADC overcome treatment resistance? 

A dual-payload ADC overcomes treatment resistance through a "Dual-Strike Strategy" that conjugates two complementary toxins onto a single antibody to deliver a multi-dimensional attack. This design ensures that even if some cells are naturally resistant to one toxin, the second "mechanistically distinct" toxin can still kill them.  Additionally, it prevents resistance by maintaining anti-tumor activity even if the tumor becomes resistant to one of the payload mechanisms, ultimately delivering synergistic potency and higher efficacy than co-administering separate treatments.

3. Why does BCG048 target both ITGB6 and B7-H3 in solid tumors? 

Targeting both ITGB6 and B7-H3 provides a strategic advantage through complementary biology, pairing ITGB6's role in tumor invasion and immune exclusion with B7-H3's immune checkpoint suppression. This dual targeting reduces antigen escape to cover tumor heterogeneity and offers enhanced selectivity since both targets show low expression in normal tissues. Additionally, while B7-H3 is a highly competitive target in the industry, adding ITGB6 provides mechanistic uniqueness and a strong positioning advantage.